PCP
MCID: PNM001
MIFTS: 59

Pneumocystosis (PCP)

Categories: Immune diseases, Infectious diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Pneumocystosis

MalaCards integrated aliases for Pneumocystosis:

Name: Pneumocystosis 12 74 52 58 15 17 32
Pneumocystis Jirovecii Pneumonia 12 52 3
Pneumocystis Carinii Pneumonia 12 52 15
Pneumocystis Pneumonia 12 52 3
Pcp 47 3
Pneumocystis Jiroveci Pneumonia 71
Pneumonia Pneumocystis Carinii 54
Pneumocystosis Pneumonia 12
Pulmonary Pneumocystosis 12
Pneumonia, Pneumocystis 43

Characteristics:

Orphanet epidemiological data:

58
pneumocystosis
Inheritance: Not applicable; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11339
ICD9CM 34 136.3
MeSH 43 D011020
NCIt 49 C3334
SNOMED-CT 67 415125002
ICD10 32 B59
ICD10 via Orphanet 33 B59+ J17.3*
UMLS via Orphanet 72 C1535939
Orphanet 58 ORPHA723
UMLS 71 C1535939

Summaries for Pneumocystosis

CDC : 3 Pneumocystis pneumonia (PCP) is a serious infection caused by the fungus Pneumocystis jirovecii. Most people who get PCP have a medical condition that weakens their immune system, like HIV/AIDS, or take medicines that lower the body's ability to fight germs and sickness. In the United States, people with HIV/AIDS are less likely to get PCP today than before the availability of antiretroviral therapy (ART). However, PCP is still a substantial public health problem.1-3 Much of the information we have about PCP and its treatment comes from caring for patients with HIV/AIDS. Scientists have changed both the classification and the name of this organism since it first appeared in patients with HIV in the 1980s. Pneumocystis jirovecii used to be classified as a protozoan but is now considered a fungus.4 Pneumocystis jirovecii used to be called Pneumocystis carinii. When scientists renamed P. carinii to P. jirovecii, some people considered using the abbreviation "PJP," but to avoid confusion, Pneumocystis jirovecii pneumonia is still abbreviated "PCP."5

MalaCards based summary : Pneumocystosis, also known as pneumocystis jirovecii pneumonia, is related to immunodeficiency with hyper-igm, type 1 and oral candidiasis. An important gene associated with Pneumocystosis is DHPS (Deoxyhypusine Synthase), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Prednisolone phosphate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and kidney, and related phenotypes are fever and dyspnea

Disease Ontology : 12 An opportunistic mycosis that is located in lungs, but can also occur in eyes, ears, skin, thyroid, pituitary, palate, parathyroid, esophagus, pleura, heart, liver, spleen, small intestine, adrenals, kidneys, bone marrow, and lymph nodes, has material basis in Pneumocystis jirovecii that effects interstitial and alveolar tissues and has symptom nonproductive cough, has symptom shortness of breath, and has symptom fever.

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 723 Definition Human pneumocystosis is caused by an infectious agent, which (after recent nomenclature and taxonomy revisions) is now classed as the fungus Pneumocystis jiroveci . The prevalence is unknown. Pneumocystis jiroveci is an opportunistic infectious agent, developing in immunosuppressed patients. It is an air-borne infection, localised to the lungs. However, extrapulmonary involvement is seen in AIDS patients. The disease manifests progressively with coughing, respiratory problems (dyspnea) and fever, followed by acute respiratory insufficiency and death within a few weeks in untreated cases. The most reliable diagnostic method is bronchoalveolar lavage. The treatment of choice is cotrimoxazole. Visit the Orphanet disease page for more resources.

Wikipedia : 74 Pneumocystosis is an infection by Pneumocystis jirovecii, that primarily occurs as a pulmonary infection... more...

Related Diseases for Pneumocystosis

Diseases related to Pneumocystosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1045)
# Related Disease Score Top Affiliating Genes
1 immunodeficiency with hyper-igm, type 1 33.1 CD40LG CD4 CCR6
2 oral candidiasis 31.3 CLEC7A CD8A CD4 CCR6
3 esophageal candidiasis 31.0 CD8A CD4 CCR6 CARTPT
4 t cell deficiency 31.0 CD8A CD40LG CD4 CCR6
5 cryptococcal meningitis 31.0 CD8A CD4 CCR6 CARTPT
6 iga glomerulonephritis 31.0 CD40LG CCR6 ALB
7 posterior scleritis 30.9 TNF CRP
8 autoimmune glomerulonephritis 30.8 CD8A CD4 CCR6
9 toxoplasmosis 30.8 TNF IL6 DHFR CD40LG
10 chronic graft versus host disease 30.7 CD4 ALB
11 haemophilus influenzae 30.7 TNF CLEC7A
12 ulcerative colitis 30.7 TNF IL6 CRP CCR6
13 rapidly progressive glomerulonephritis 30.7 CRP CD40LG ALB
14 genital herpes 30.6 CD8A CD40LG CD4 CCR6
15 adult respiratory distress syndrome 30.6 TNF SFTPD IL6 CSF3
16 immune deficiency disease 30.6 TNF IL6 CD40LG CD4 CCR6
17 scabies 30.6 CSF3 CD4 CCR6
18 neutropenia 30.6 TNF IL6 CSF3 CRP CD40LG ALB
19 pulmonary edema 30.6 TNF CSF3 CRP
20 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 30.6 CSF3 CRP ALB
21 extrinsic allergic alveolitis 30.6 SFTPD IL6 CCR6 ALB
22 chronic granulomatous disease 30.5 TNF MT-CYB CSF3 CD40LG
23 cryptosporidiosis 30.5 DHFR CSF3 CD8A CD40LG CD4
24 drug allergy 30.5 CRP CD40LG CD4 ALB
25 leukemia, acute lymphoblastic 30.5 DHFR CSF3 CD8A CD40LG CD4 CCR6
26 pustulosis of palm and sole 30.5 TNFRSF1B TNF CRP CCR6
27 portal hypertension 30.5 TNF CD40LG CD4 ALB
28 pyoderma gangrenosum 30.4 TNFRSF1B TNF CSF3 CCR6
29 hepatitis e 30.4 TNF CD40LG ALB
30 neuromyelitis optica 30.4 IL6 CRP CD40LG
31 purpura 30.4 TNF IL6 CRP CD40LG
32 allergic hypersensitivity disease 30.4 TNF SFTPD CD4 CCR6
33 cryptococcosis 30.4 TNF CLEC7A CD8A CD4 CCR6
34 pleural empyema 30.4 FLNC CRP CD40LG CD4 ALB
35 giardiasis 30.4 CD8A CD40LG CD4 ALB
36 pulmonary tuberculosis 30.4 TNF IL6 CRP ALB
37 toxic shock syndrome 30.4 TNF IL6 CRP CD40LG
38 swine influenza 30.4 TNF CD8A CD4
39 eosinophilic pneumonia 30.3 SFTPD MUC1 IL6
40 scleritis 30.3 TNFRSF1B TNF CRP CCR6
41 central nervous system lymphoma 30.3 TNF IL6 CCR6
42 end stage renal disease 30.3 TNF IL6 CRP ALB
43 coccidioidomycosis 30.3 TNF CLEC7A CD40LG CD4 CCR6
44 amebiasis 30.3 TNF CD40LG CD4 ALB
45 retinal vein occlusion 30.3 TNF IL6 CD40LG
46 acute myocarditis 30.3 TNF CRP CD4
47 disseminated intravascular coagulation 30.3 TNF IL6 CRP
48 visceral leishmaniasis 30.3 TNF CRP ALB
49 collagen disease 30.3 SFTPD CRP CD40LG CCR6
50 pfeiffer syndrome 30.2 CD8A CD40LG CD4 CCR6

Comorbidity relations with Pneumocystosis via Phenotypic Disease Network (PDN):


Deficiency Anemia Heart Disease
Neutropenia Oral Candidiasis
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Pneumocystosis:



Diseases related to Pneumocystosis

Symptoms & Phenotypes for Pneumocystosis

Human phenotypes related to Pneumocystosis:

58 (show all 23)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 Very frequent (99-80%)
2 dyspnea 58 Very frequent (99-80%)
3 immunodeficiency 58 Frequent (79-30%)
4 weight loss 58 Frequent (79-30%)
5 respiratory insufficiency 58 Frequent (79-30%)
6 neoplasm 58 Occasional (29-5%)
7 respiratory failure 58 Frequent (79-30%)
8 respiratory failure requiring assisted ventilation 58 Frequent (79-30%)
9 increased antibody level in blood 58 Frequent (79-30%)
10 hypoxemia 58 Very frequent (99-80%)
11 pleural effusion 58 Frequent (79-30%)
12 exertional dyspnea 58 Frequent (79-30%)
13 interstitial pneumonitis 58 Frequent (79-30%)
14 increased lactate dehydrogenase activity 58 Occasional (29-5%)
15 acute infectious pneumonia 58 Very frequent (99-80%)
16 nonproductive cough 58 Frequent (79-30%)
17 abnormal neutrophil count 58 Frequent (79-30%)
18 chronic oral candidiasis 58 Occasional (29-5%)
19 parenchymal consolidation 58 Occasional (29-5%)
20 pneumocystis jirovecii pneumonia 58 Very frequent (99-80%)
21 combined cystic and ground-glass pattern on pulmonary hrct 58 Frequent (79-30%)
22 multiple pulmonary cysts 58 Occasional (29-5%)
23 bloodstream infectious agent 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Pneumocystosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB CCR6 CD52 CLEC7A CSF3 FLNC

MGI Mouse Phenotypes related to Pneumocystosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 CABIN1 CARTPT CCR6 CD4 CD40LG CD8A
2 homeostasis/metabolism MP:0005376 10 ALB CARTPT CCR6 CD4 CD40LG CLEC7A
3 immune system MP:0005387 9.86 ALB CABIN1 CARTPT CCR6 CD4 CD40LG
4 integument MP:0010771 9.28 CD4 CD40LG CD8A CSF3 DHFR FLNC

Drugs & Therapeutics for Pneumocystosis

Drugs for Pneumocystosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
7
Sulfisoxazole Approved, Vet_approved Phase 4 127-69-5 5344
8
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
9 Antiviral Agents Phase 4
10 Anti-Retroviral Agents Phase 4
11 Protective Agents Phase 4
12 Methylprednisolone Acetate Phase 4
13 Neuroprotective Agents Phase 4
14 Immunoglobulins Phase 4
15 Antibodies Phase 4
16
Zidovudine Approved Phase 3 30516-87-1 35370
17
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
19
Zalcitabine Approved, Investigational Phase 3 7481-89-2 24066
20
Hydroxychloroquine Approved Phase 3 118-42-3 3652
21
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
24
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
25
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
26
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
27
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
28
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
29
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
30
Allopurinol Approved Phase 3 315-30-0 2094
31
Nelfinavir Approved Phase 3 159989-64-7 64143
32
Efavirenz Approved, Investigational Phase 3 154598-52-4 64139
33
Lamivudine Approved, Investigational Phase 3 134678-17-4 60825
34
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
35
Darunavir Approved Phase 3 206361-99-1, 635728-49-3 213039
36
Cobicistat Approved Phase 3 1004316-88-4
37
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
38
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
39
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
40
Trimetrexate Approved, Investigational Phase 3 52128-35-5 5583
41
Isoniazid Approved, Investigational Phase 2, Phase 3 54-85-3 3767
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
43 Molgramostim Investigational Phase 3 99283-10-0
44
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
45
Pafuramidine Investigational Phase 3 186953-56-0
46 Gastrointestinal Agents Phase 3
47 Antiemetics Phase 3
48 Reverse Transcriptase Inhibitors Phase 3
49 Amebicides Phase 3
50 Liposomal amphotericin B Phase 3

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Gradual Initiation of Trimethoprim/Sulfamethoxazole as Primary Pneumocystis Carinii Pneumonia Prophylaxis Completed NCT00000816 Phase 4 Sulfamethoxazole-Trimethoprim
3 Randomized Clinical Trial to Assess Whether the Duration of Cotrimoxazole Preventive Therapy in HIV Patients With CD4 Counts >350 CD4 Cells/µL by Antiretroviral Treatment Influences the Rate of Carriage of Multidrug-resistant Bacteria Completed NCT03087890 Phase 4 Cotrimoxazole;Placebo
4 Population Pharmacokinetic Analysis of Sulfamethoxazole and Trimethoprim in Normal Weight, Overweight, and Obese Volunteers Completed NCT01167452 Phase 4 Sulfamethoxazole/trimethoprim
5 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study) Completed NCT01417949 Phase 4
6 A Prospective Randomized Controlled Study to Compare Efficacy of Caspofungin Combined With Trimethoprim-sulfamethoxazole Versus Trimethoprim/Sulfamethoxazole as First-line Therapy in Non-HIV Patients With Severe Pneumocystis Pneumonia Recruiting NCT03978559 Phase 4 caspofungin;TMP/SMZ(trimethoprim/sulfisoxazole);Methylprednisolone
7 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Recruiting NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
8 Oral Corticosteroids Therapy and Interstitial Fibrosis in Patients With Pneumocystis Jirovecii Pneumonia (PCP) and pO2 of >70 at Presentation. Withdrawn NCT00636935 Phase 4 Antibiotics only;Antibiotics + Corticosteroids;Corticosteroids + antibiotics
9 The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases Unknown status NCT01747278 Phase 2, Phase 3 Trimethoprim/Sulfamethoxazole
10 A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides Completed NCT00000802 Phase 3 Atovaquone;Dapsone
11 A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients Completed NCT00000748 Phase 3 Sulfamethoxazole-Trimethoprim
12 A Randomized, Comparative, Prospective Study of Monthly Aerosolized Pentamidine and Thrice Weekly Dapsone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant to Trimethoprim and/or Sulfonamides Completed NCT00001028 Phase 3 Pentamidine isethionate;Dapsone
13 A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS Completed NCT00001013 Phase 3 Trimetrexate glucuronate;Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Leucovorin calcium
14 A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Pneumonia in AIDS Completed NCT00000715 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim
15 A Randomized, Open-Label Trial of High Dose Atovaquone Versus Low Dose Atovaquone Versus Aerosolized Pentamidine for Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With HIV Infection Who Are Intolerant of TMP/SMX Completed NCT00002340 Phase 3 Atovaquone;Pentamidine isethionate
16 A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole in the Treatment of Mild-to-Moderate PCP in Patients With AIDS Completed NCT00000640 Phase 3 Primaquine;Sulfamethoxazole-Trimethoprim;Dapsone;Clindamycin
17 A Controlled Comparative Trial of Trimethoprim - Sulfamethoxazole Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT) Completed NCT00000727 Phase 3 Pentamidine isethionate;Pyrimethamine;Sulfamethoxazole/Trimethoprim;Sulfadoxine/Pyrimethamine;Zidovudine
18 A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia Completed NCT00000724 Phase 3 Trimetrexate glucuronate;Leucovorin calcium
19 A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies Completed NCT00001016 Phase 3 Trimetrexate glucuronate;Leucovorin calcium
20 A Randomized, Comparative, Double-Blind Trial of Trimetrexate (CI-898) With Leucovorin Calcium Rescue Versus Trimethoprim / Sulfamethoxazole for Moderately Severe Pneumocystis Carinii Pneumonia in Patients With AIDS Completed NCT00001014 Phase 3 Trimetrexate glucuronate;Sulfamethoxazole-Trimethoprim;Leucovorin calcium
21 An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies Completed NCT00000714 Phase 3 Trimetrexate glucuronate;Leucovorin calcium
22 A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection Completed NCT00000991 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Dapsone;Zidovudine
23 A Randomized, Unblinded Trial of Zidovudine Versus ddC in the Treatment of Patients Status Post PCP Who Received Long-Term Zidovudine Therapy in Protocol ACTG 002 Completed NCT00000682 Phase 3 Zidovudine;Zalcitabine
24 A Multi-Center Clinical Trial To Evaluate Azidothymidine (AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Infection in Patients With AIDS Post First Episode PCP Completed NCT00000700 Phase 3 Zidovudine
25 Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19 Completed NCT04261517 Phase 3 Hydroxychloroquine
26 A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy Completed NCT00000651 Phase 3 Zidovudine;Zalcitabine
27 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
28 A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma Completed NCT00000658 Phase 3 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone
29 Randomized Study to Evaluate Immediate Potent Antiretroviral Therapy for HIV-Infected Subjects With CD4 Cell Counts Less Than 350 Cells/mm3 Admitted to Intensive Care Areas With an AIDS-Defining Illness, Pneumonia, or Sepsis Completed NCT00028327 Phase 3 Lamivudine/Zidovudine;Nelfinavir mesylate;Efavirenz;Lamivudine;Zidovudine
30 Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine Completed NCT00970879 Phase 3 cotrimoxazole;mefloquine
31 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
32 Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC Recruiting NCT02944045 Phase 3 Methylprednisolone;Placebo
33 Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 Recruiting NCT04252274 Phase 3 Darunavir and Cobicistat
34 A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study) Recruiting NCT04368559 Phase 3 Rezafungin for Injection;Posaconazole;Fluconazole;Trimethoprim-sulfamethoxazole (TMP/SMX);Intravenous Placebo;Oral Placebo
35 Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Active, not recruiting NCT03393000 Phase 3 Trans Sodium Crocetinate plus SOC
36 A Randomized, Comparative Trial of Trimetrexate With Leucovorin Rescue Versus Standard Anti-Pneumocystis Therapy Versus Standard Anti-Pneumocystis Therapy With High Dose Steroids for AIDS Patients With Pneumocystis Pneumonia Who Appear to Be Refractory to Conventional Drugs Terminated NCT00000730 Phase 3 Trimetrexate glucuronate;Methylprednisolone;Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Leucovorin calcium
37 International Randomized, Controlled Phase 3 Trial of DB289 Versus Trimethoprim-sulfamethoxazole for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP) in Patients With HIV/AIDS Terminated NCT00302341 Phase 3 Pafuramidine maleate (DB289);Trimethoprim-Sulfamethoxazole (TMP-SMX)
38 A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV Terminated NCT00080119 Phase 2, Phase 3 Isoniazid (INH);Trimethoprim/Sulfamethoxazole (TMP/SMX);Isoniazid Placebo (PL)
39 A Controlled Randomized Trial to Study the Efficacy of Adjunctive Methylprednisolone for the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Pediatric AIDS Patients Withdrawn NCT00000741 Phase 3 Methylprednisolone
40 A Phase II Open Randomized Comparison of 566C80 and Pentamidine Isethionate for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Who Are Intolerant of Trimethoprim / Sulfamethoxazole Completed NCT00001996 Phase 2 Atovaquone;Pentamidine isethionate
41 A Randomized, Double-Blind Study of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients Completed NCT00000655 Phase 2 Atovaquone;Sulfamethoxazole-Trimethoprim
42 A Phase II Study of WR 6026 for Pneumocystis Carinii Pneumonia in People With HIV Infection Completed NCT00000863 Phase 2 Sitamaquine
43 A Randomized, Phase II/III, Double-Blind, Two-Armed Study of Micronized Atovaquone and Azithromycin (AT/AZ) as Compared to Trimethoprim-Sulfamethoxazole (TMP/SMX) in the Prevention of Serious Bacterial Infections When Used in Children Aged 3 Months to 19 Years With HIV Infection Completed NCT00000811 Phase 2 Azithromycin;Atovaquone;Sulfamethoxazole-Trimethoprim
44 A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment Completed NCT00000671 Phase 2 Zidovudine;Didanosine
45 Comparison of 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine in Therapy of Patients With HIV Infection Completed NCT00000979 Phase 2 Zidovudine;Didanosine
46 Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study Completed NCT00590681 Phase 2 Bevacizumab and Temozolomide
47 A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3 Completed NCT00000712 Phase 2 Zidovudine;Acyclovir
48 An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex Completed NCT00000672 Phase 2 Didanosine
49 A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation Completed NCT01246206 Phase 2 Tacrolimus and Thymoglobulin
50 Randomized, Multi-Center Comparative Trial of Tacrolimus w/Steroids and Standard Daclizumab Induction vs a Novel Steroid-Free Tacrolimus Based Immunosuppression Protocol w/ Extended Daclizumab Induction in Pediatric Renal Transplantation Completed NCT00141037 Phase 1, Phase 2 Daclizumab;Mycophenolate mofetil (MMF);Prednisone;Tacrolimus;Ganciclovir;Valganciclovir;Trimethoprim and sulfamethoxazole

Search NIH Clinical Center for Pneumocystosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Atovaquone
CLINDAMYCIN PHOSPHATE PWDR
Pentamidine
Pentamidine Isethionate
Sulfadoxine
TRIMETHOPRIM SULFATE
Trimetrexate

Cochrane evidence based reviews: pneumonia, pneumocystis

Genetic Tests for Pneumocystosis

Anatomical Context for Pneumocystosis

MalaCards organs/tissues related to Pneumocystosis:

40
Lung, Skin, Kidney, Colon, Liver, Bone Marrow, Bone

Publications for Pneumocystosis

Articles related to Pneumocystosis:

(show top 50) (show all 2121)
# Title Authors PMID Year
1
Absence of Pneumocystis jirovecii dihydropteroate synthase gene mutations among samples from a group of AIDS patients in China. 61 54
19085210 2009
2
Structural analysis of a holoenzyme complex of mouse dihydrofolate reductase with NADPH and a ternary complex with the potent and selective inhibitor 2,4-diamino-6-(2'-hydroxydibenz[b,f]azepin-5-yl)methylpteridine. 54 61
18703847 2008
3
Caspase-9 as a target for Pneumocystis pneumonia therapy. 61 54
17169033 2006
4
Pneumocystosis: survey and DHPS genotype analysis in 14 Parisian hospitals in 2003 and 2004. 61 54
17169018 2006
5
Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. 61 54
15867494 2005
6
Cloning of the Pneumocystis jirovecii trifunctional FAS gene and complementation of its DHPS activity in Escherichia coli. 54 61
15531210 2004
7
Pneumocystis jiroveci isolates with dihydropteroate synthase mutations in patients with chronic bronchitis. 61 54
15175932 2004
8
Pneumocystis jirovecii dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France. 61 54
15200857 2004
9
Pneumocystis jirovecii dihydropteroate synthase genotypes in French patients with pneumocystosis: a 1998-2001 prospective study. 61 54
14725329 2003
10
Multilocus genotyping of Pneumocystis jirovecii in patients developing diverse forms of parasitism: implication for a wide human reservoir for the fungus. 61 54
14736212 2003
11
Pneumocystis carinii pneumonia in a term newborn infant with a transiently depressed T lymphocyte count, primarily of cells carrying the CD4 antigen. 61 54
8496763 1993
12
Pneumocystis pneumonia after lung transplantation: A retrospective multicenter study. 61
32442112 2020
13
Pneumocystis Pneumonia: Checkpoint Inhibition to the Rescue? 61
32109143 2020
14
A Critical Role for CARD9 in Pneumocystis Pneumonia Host Defense. 61
32548948 2020
15
A Rare Case of 4 Ps: Bilateral Pneumothoraces and Pneumomediastinum in Pneumocystis Pneumonia. 61
32481782 2020
16
Scientific rationale for inhaled caspofungin to treat Pneumocystis pneumonia: A therapeutic innovation likely relevant to investigate in a near future…. 61
32194238 2020
17
Detection of anti-Pneumocystis jirovecii antibodies in human serum using a recombinant synthetic multi-epitope kexin-based antigen. 61
32557324 2020
18
Reply to: Scientific rationale for inhaled caspofungin to treat Pneumocystis pneumonia: A therapeutic innovation likely relevant to investigate in a near future. 61
32194235 2020
19
Reply to the reply to Scientific rationale for inhaled caspofungin to treat Pneumocystis pneumonia: A therapeutic innovation likely relevant to investigate in a near future …. 61
32276043 2020
20
Timing of antiretroviral therapy for HIV-infected patients with moderate to severe Pneumocystis pneumonia: study protocol for a multi-centre prospective randomised controlled trial. 61
32571429 2020
21
PD-1 Deficiency Promotes Macrophage Activation and T-Helper Cell Type 1/T-Helper Cell Type 17 Response in Pneumocystis Pneumonia. 61
32048861 2020
22
Burden of serious fungal infections in the Netherlands. 61
32297377 2020
23
Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis. 61
32506311 2020
24
Assessing the Quality of Human Immunodeficiency Virus Care in Nursing Homes. 61
32052860 2020
25
Acute-Onset Metabolic Acidosis in a Woman with Pneumocystis Pneumonia. 61
32469652 2020
26
COVID-19: to be or not to be; that is the diagnostic question. 61
32522844 2020
27
It's not all about COVID-19: pneumocystis pneumonia in the era of a respiratory outbreak. 61
32558276 2020
28
Withholding primary PcP prophylaxis in virologically suppressed HIV patients: An emulation of a pragmatic trial in COHERE. 61
32448894 2020
29
Etiologies and outcomes of rheumatology patients with acute respiratory failure requiring intensive care: a single-center medical records review study of 259 patients. 61
32372293 2020
30
Genotyping of Pneumocystis jirovecii isolates obtained from clinical samples by multilocus sequencing: a molecular epidemiology study conducted in Turkey. 61
32274557 2020
31
Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia. 61
32391396 2020
32
CD4+ T cell lymphopenia predicts mortality from Pneumocystis pneumonia in kidney transplant patients. 61
32277846 2020
33
Role of Pneumocystis jirovecii infection in chronic obstructive pulmonary disease progression in an immunosuppressed rat Pneumocystis pneumonia model. 61
32256801 2020
34
Pneumonia Caused by Three Separate Microorganisms Simultaneously in a Patient Infected with Human Immunodeficiency Virus. 61
32467781 2020
35
Recent Advances in the Diagnosis and Management of Pneumocystis Pneumonia. 61
32185915 2020
36
HIV patients dying on anti-tuberculosis treatment: are undiagnosed infections still a problem in French Guiana? 61
32276647 2020
37
Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab. 61
32160881 2020
38
Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies. 61
32198645 2020
39
[Clinical features and prognosis of pneumocystis pneumonia in patients treated with rituximab for autoimmune diseases]. 61
32164117 2020
40
Frequency of Invasive Fungal Disease in Adults: Experience of a Specialized Laboratory in Medellín, Colombia (2009-2015). 61
32244949 2020
41
Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. 61
30487148 2020
42
Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study. 61
32041539 2020
43
Opportunistic infections after conversion to belatacept in kidney transplantation. 61
32030416 2020
44
BAL fluid analysis in the identification of infectious agents in patients with hematological malignancies and pulmonary infiltrates. 61
31073843 2020
45
Pneumocystis jiroveci. 61
32000290 2020
46
Use of glucocorticoids in the critical care setting: Science and clinical evidence. 61
31626870 2020
47
Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. 61
31743846 2020
48
Disseminated Pneumocystosis in a Toy Poodle. 61
32138848 2020
49
Failures of once-a-week trimethoprim-sulfamethoxazole prophylaxis in children undergoing allogeneic hematopoietic stem cell transplant. 61
31846143 2020
50
Pneumocystis primary infection in infancy: Additional French data and review of the literature. 61
31127850 2020

Variations for Pneumocystosis

Expression for Pneumocystosis

Search GEO for disease gene expression data for Pneumocystosis.

Pathways for Pneumocystosis

Pathways related to Pneumocystosis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 TNFRSF1B TNF MUC1 IL6 FLNC CSF3
2
Show member pathways
13.27 TNFRSF1B TNF MUC1 IL6 CSF3 CD40LG
3
Show member pathways
13.15 TNFRSF1B TNF IL6 FLNC CSF3 CD40LG
4
Show member pathways
12.76 TNF IL6 CD8A CD40LG CD4
5
Show member pathways
12.49 TNF IL6 CD8A CD40LG CD4
6 12.45 TNFRSF1B TNF CD8A CD40LG CABIN1
7
Show member pathways
12.22 TNFRSF1B TNF IL6 CCR6
8
Show member pathways
12.19 TNF IL6 DHFR CRP ALB
9
Show member pathways
12.08 TNF SFTPD MUC1 IL6
10 11.85 TNFRSF1B TNF MUC1 IL6
11
Show member pathways
11.71 TNFRSF1B TNF CD40LG
12
Show member pathways
11.66 TNF CD40LG CABIN1
13
Show member pathways
11.63 TNFRSF1B TNF CD40LG
14 11.62 TNF IL6 CSF3 CD8A CD4
15 11.61 TNF CD8A CD4 CCR6
16
Show member pathways
11.55 TNF IL6 CD40LG
17 11.54 TNF IL6 CSF3
18 11.54 TNF IL6 CD8A CD4
19 11.35 TNF IL6 CSF3 CD8A CD4
20 11.32 TNF IL6 CSF3 CD40LG
21 11.28 CD8A CD40LG CD4
22 11.25 TNFRSF1B TNF IL6 CSF3
23 11.18 TNF IL6 DHFR
24 10.89 TNF IL6 CRP
25 10.39 TNF IL6 CSF3 CD4

GO Terms for Pneumocystosis

Cellular components related to Pneumocystosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TNF SFTPD MUC1 IL6 CSF3 CRP
2 external side of plasma membrane GO:0009897 9.55 TNF CD8A CD40LG CD4 CCR6
3 extracellular region GO:0005576 9.4 TNFRSF1B TNF SFTPD MUC1 IL6 CSF3

Biological processes related to Pneumocystosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.76 TNFRSF1B TNF IL6 CSF3
2 inflammatory response GO:0006954 9.73 TNFRSF1B TNF IL6 CRP CLEC7A CD40LG
3 positive regulation of T cell proliferation GO:0042102 9.67 IL6 CD40LG CD4
4 humoral immune response GO:0006959 9.65 TNF IL6 CCR6
5 cytokine-mediated signaling pathway GO:0019221 9.63 TNFRSF1B TNF MUC1 IL6 CSF3 CD4
6 T cell activation GO:0042110 9.61 CLEC7A CD8A CD4
7 positive regulation of phagocytosis GO:0050766 9.54 TNF SFTPD CLEC7A
8 regulation of neuroinflammatory response GO:0150077 9.51 TNFRSF1B IL6
9 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.5 TNF IL6 CLEC7A
10 regulation of immunoglobulin secretion GO:0051023 9.4 TNF CD40LG
11 immune response GO:0006955 9.23 TNFRSF1B TNF IL6 CSF3 CD8A CD40LG
12 negative regulation of lipid storage GO:0010888 9.13 TNF IL6 CRP

Molecular functions related to Pneumocystosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 CSF3 CD40LG

Sources for Pneumocystosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....